Aortica Corporation was founded to design, manufacture, and market tools for treatment of patients with AAA disease who have aortic anatomy that limits their treatment options. While EVAR has become a highly desirable option for treatment of AAA disease, approximately 40% of patients are not candidates for EVAR because their aortic anatomy is structured in a manner that does not allow an endograft to be anchored properly without blocking blood flow to vital organs. These patients face either open surgery or may be treated sub-optimally with standard EVAR.
Personalized Vascular Therapy
Our Mission & Vision
We envision a future where Simplified FEVAR & Personalized Vascular Therapy become the standard of care, allowing more physicians to treat more patients with complex AAA disease. We will achieve our objectives through both invention and innovation – developing and continuously improving therapeutic options that deliver minimally invasive, highly effective treatment options to all patients in our target markets.